Last updated: June 26, 2026

Bicillin C-R 900/300 (benzathine penicillin G + procaine penicillin G) market dynamics and financial trajectory

Bicillin C-R 900/300 is a US injectable combination of benzathine penicillin G (long-acting) plus procaine penicillin G (intermediate-acting). The product’s market dynamics are driven by (1) clinician preference for single-dose depot penicillin for specific infections, (2) payer formularies and hospital purchasing contracts, (3) antibiotic stewardship and shifting prescribing for skin/respiratory infections, and (4) supply reliability of sterile injectables. The financial trajectory is typically stable-to-moderate because the drug class is off-patent and faces generic and/or private-label competition, while volumes are sensitive to incidence and guideline-driven use.

What is Bicillin C-R 900/300 and what therapeutic niche drives demand?

Quick answer: The “C-R” depot penicillin is used for infections where penicillin is appropriate and a long-acting regimen improves adherence and dosing logistics.

Mechanism and dosing practicality

Depot formulation combines:
- Benzathine penicillin G: prolonged absorption supporting extended antimicrobial exposure.
- Procaine penicillin G: faster initial release.
Clinical value centers on:
- fewer doses versus immediate-release penicillin schedules,
- suitability for office/clinic or infusion-center administration,
- reduced need for patient adherence to multiple daily doses.

Primary use-cases

Demand is pulled by guideline-concordant prescribing for:

streptococcal pharyngitis/tonsillitis (where penicillin is indicated and injectable regimens are chosen),
rheumatic fever prophylaxis in appropriate patients and settings,
select skin and soft tissue infections when penicillin is appropriate and local resistance patterns support it,
other penicillin-susceptible bacterial infections where depot penicillin is clinically preferred by protocols.

What most affects utilization

Antibiotic stewardship initiatives that reduce inappropriate penicillin use.
Substitution pressures toward oral options (where adherence support exists) and toward other injectables (where protocols favor them).
Patient population shifts:
- pediatric and underserved populations often increase depot penicillin usage,
- seasonal variation in respiratory pathogens influences volume.

How does the US market for Bicillin C-R 900/300 behave: pricing, contracts, and channel structure?

Quick answer: Sales tend to track institutional purchasing cycles and payer contracting more than retail consumer demand, with price pressure from generic/private-label substitutes and periodic supply disruptions.

Channel drivers

Hospital and clinic systems account for the bulk of injectable antibiotics.
Group purchasing organizations (GPOs) and IDN formularies influence:
- which NDCs are stocked,
- whether substitution is permitted at the product class level,
- tender-based procurement pricing.

Pricing dynamics for off-patent depot penicillins

Bicillin C-R is not a “protected brand” economics story in the way specialty drugs are.
Financial outcomes are shaped by:
- margin compression from multi-source competition,
- list-price vs net-price gap tied to rebates and contracting,
- tender wins that can swing volumes quarter-to-quarter.

Supply and manufacturing reliability

Sterile injectable antibiotics are exposed to:

batch-release constraints,
aseptic manufacturing throughput,
raw material and packaging availability,
sterile fill-finish capacity. Supply tightness can temporarily lift net pricing and improve short-run revenue but can also trigger missed demand when backorders occur.

Which competitors and substitute therapies impact Bicillin C-R 900/300 sales?

Quick answer: Competitive pressure comes from other benzathine/procaine penicillin products, generic depot penicillins, and substituted regimens (oral penicillins/amoxicillin or alternative injectables) depending on guideline pathways.

Direct product competition (same class, depot penicillin)

Other benzathine penicillin G formulations (commonly single-ingredient depot products).
Other benzathine plus procaine or equivalent depot combinations.
Authorized generics/private-label products in institutional distribution.

Indirect competition (clinical substitution)

Oral penicillin-class options where adherence can be supported.
For some indications, clinicians may choose non-penicillin antibiotics if:
- local susceptibility patterns shift,
- patient penicillin allergy management protocols steer therapy,
- stewardship targets reduce injectables unless necessary.

How substitution shows up financially

Net sales can flatten even if total antibiotic incidence remains stable, if formularies shift to cheaper or preferred SKUs.
Conversely, depot penicillin demand can rise during periods when oral access is limited or adherence is hard.

When do generic entry risks exist for Bicillin C-R 900/300 and how do they affect revenue?

Quick answer: Generic entry pressure is structurally high for depot penicillins because the active ingredients are longstanding and most product-level protections are limited or expired, making revenue sensitive to availability of lower-cost multisource products.

Patent estate reality for established penicillin depots

For older antibiotic products, the main revenue risk typically comes from:
- product formulation or manufacturing patents that may expire,
- exclusivity that is not comparable to modern biologics/specialty pathways,
- competition from established generic manufacturers with scale.

Paragraph IV and litigation

For legacy antibiotics, Paragraph IV dynamics can occur, but the core effect for revenue is typically from post-entry price erosion rather than prolonged exclusivity fights.
Financial trajectories usually look like:
- stable sales while a brand is still treated as preferred,
- step-down after multi-source tender expansion and SKU switches.

Net effect on financial trajectory

Expect declining gross margin and slower revenue growth after increased generic availability.
Volume can remain resilient in institutional settings if clinicians and formularies keep depot penicillin in therapeutic stock.

What is the Orange Book status of Bicillin C-R 900/300 and what does it imply for exclusivity?

Quick answer: A complete Orange Book–driven exclusivity and patent mapping requires the Orange Book listing for the exact drug product and strength. Without that listing text, the status cannot be stated accurately for this specific NDC/strength.

Why Orange Book status matters for forecasting

Determines whether product-level exclusivities (e.g., new chemical entity or approvals tied to exclusivity) apply.
Identifies whether formulation or manufacturing patents constrain generic entry.
Drives probability-weighted revenue erosion timing.

Financial linkage

If the product is fully off-patent with no active exclusivity, forecasting should emphasize:
- tender pricing,
- multisource supply reliability,
- SKU preference shifts.

How does FDA and labeling guidance influence Bicillin C-R 900/300 prescribing and demand?

Quick answer: FDA labeling and safety communication drive clinician comfort and institutional protocol inclusion, while stewardship programs and evolving treatment guidance indirectly affect injectable antibiotic utilization.

Label and safety

Depot penicillin prescribing is shaped by:

allergy and hypersensitivity warning requirements,
guidance on administration and dosing schedules,
contraindication and precaution language that affects patient eligibility.

Stewardship and guideline alignment

When guidelines recommend alternative first-line regimens for common infections, depot penicillin can see indirect volume pressure.
When patient factors favor injectable therapy (adherence limitations, clinical severity, outpatient constraints), depot penicillin can regain share.

What are the key financial metrics to track for Bicillin C-R 900/300?

Quick answer: For legacy injectables, investors and business teams should track net sales and margin trends, tender-based volume shifts, and supply-driven revenue volatility rather than R&D-led growth.

Primary KPIs

Net sales by quarter and by major distribution channel.
Net price trend (net vs wholesaler/distributor list pricing).
Gross margin and manufacturing cost per dose.
Inventory and backorder days (linked to fill-finish and batch-release).
Contracting impact:
- GPO/IDN tender wins or loss frequency,
- formulary inclusion or restriction changes.
Product availability:
- shortages, partial allocations, and service levels.
Customer concentration in hospital systems that drive contract volume.

Common financial pattern in off-patent injectables

Sales may be relatively stable in volume terms but volatile in net pricing due to contracting and supply.
Margin compresses as more low-cost sources participate.
Occasional step changes occur after:
- manufacturing recoveries or failures,
- major IDN formulary refreshes.

How do supply shortages and manufacturing disruptions change quarterly sales for depot penicillins?

Quick answer: Supply tightness increases the probability of missed doses and can cap revenue even if pricing rises; once supply stabilizes, volume normalization can cause revenue swings in either direction.

Shortage-driven dynamics

When supply is constrained:
- distributors ration allocations,
- hospitals defer elective dosing or switch to alternatives,
- demand is lost rather than priced up.
The revenue impact depends on:
- whether the product remains the preferred SKU during shortage,
- whether clinicians switch to therapeutic alternatives.

Release-and-normalize

When production stabilizes:
- fill rates improve,
- contracts replenish stock,
- revenue can overshoot briefly due to catch-up demand.

How does Bicillin C-R 900/300 compare with other depot penicillin products commercially?

Quick answer: Commercial performance typically tracks preferred SKU status within institutional formularies and the ability to maintain uninterrupted supply; products with fewer multisource competitors or more favorable contract positioning hold share better.

Comparison dimensions

NDC multiplicity and multisource depth in the same strength:
- more competitors typically means lower net pricing.
Tender and formulary status:
- preferred alternatives can be swapped without additional prescriber effort.
Patient administration logistics:
- if administration protocols are aligned with a specific combination product, it can outperform more basic depot products.

What litigation or settlements affect Bicillin C-R 900/300 market outcomes?

Quick answer: For established depot antibiotics, litigation usually matters only if it delays generic availability of an equivalent product; absent product-specific suit/settlement data for this exact drug product, no litigation effect can be attributed.

Where litigation would show up financially

Delayed generic launch leads to a temporary pricing or volume shield.
Settlement terms can include “no-ship” windows or launch carve-outs that stabilize net sales for the period of effect.

What generic entry and competitive launch scenarios are most likely for Bicillin C-R 900/300?

Quick answer: The most likely scenario is continued price erosion and incremental share redistribution as additional authorized generics and multisource SKUs compete for institutional tenders.

Scenario set for business planning

Base case: stable volume, declining net price as contract cycles re-optimize sourcing.
Downside: supply constraints plus intensified low-cost competition reduces share and net pricing.
Upside: stable supply and preferred SKU status during seasonal peaks sustains volume and limits price erosion.

Key Takeaways

Bicillin C-R 900/300 demand is driven by depot penicillin clinical niche where injectable dosing logistics and adherence matter, with utilization influenced by antibiotic stewardship and guideline-directed substitution.
Financial trajectory in mature depot antibiotic categories typically reflects net price compression and tender-driven volume shifts more than innovation-led growth.
Supply reliability is a primary swing factor for quarterly results: tight availability can cap revenue via lost demand and protocol switching, while stabilization can enable catch-up volume.
Competitive risk is structural: off-patent active ingredients and multicompiler generic pressure usually lead to ongoing net pricing erosion and SKU substitution in institutional procurement.
A precise Orange Book exclusivity and patent-lock assessment for this exact product requires the drug product’s Orange Book listing; without the exact NDC/patent text, exclusivity timing cannot be stated reliably.

FAQs

How do hospital formularies decide between Bicillin C-R 900/300 and other benzathine/procaine depot penicillins?
By GPO/IDN tender pricing, historical utilization, availability service levels, and protocol alignment with administration logistics.
What drives seasonal demand for depot penicillin injectables like Bicillin C-R 900/300?
Respiratory infection incidence trends and pediatric/outpatient infection seasonality, with stewardship-guideline constraints moderating prescribing.
How does a supply shortage typically affect net sales of mature sterile injectable antibiotics?
It can reduce delivered volume via rationing and substitution, often limiting revenue even if list pricing rises.
What are the main cost and margin pressures for depot penicillins in the US market?
Aseptic manufacturing cost inflation, raw material/packaging availability, and net price compression from multisource competition.
What is the most common financial pattern after multisource generic entry for legacy antibiotics?
Volume may hold in institutional settings, but net price and gross margin typically decline as contracts rebid.

References (APA)

No sources are cited because the required product-specific FDA/Orange Book, patent, and financial dataset for Bicillin C-R 900/300 could not be provided in the prompt.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	3
Patent Applications:	87
What excipients (inactive ingredients) are in BICILLIN C-R 900/300?	BICILLIN C-R 900/300 excipients list
DailyMed Link:	BICILLIN C-R 900/300 at DailyMed

Sponsor	Phase
Washington University School of Medicine	PHASE3
University of Tennessee	Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms Llc	BICILLIN C-R 900/300	penicillin g benzathine; penicillin g procaine	INJECTABLE;INJECTION	050138-003	Approved Prior to Jan 1, 1982		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for BICILLIN C-R 900/300

Recent Clinical Trials for BICILLIN C-R 900/300

Pharmacology for BICILLIN C-R 900/300